Introduced to the Market in the Last Decade (2001−2011) Jiang Wang,† María Sańchez-Rosello,́‡,§ Jose ́ Luis Aceña, Carlos del Pozo,‡ Alexander E. Sorochinsky, Santos Fustero,*,‡,§ Vadim A. Soloshonok,* and Hong Liu*,† †Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China ‡Department of Organic Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicente Andreś Estelleś, 46100 Burjassot, Valencia, Spain Laboratorio de Molećulas Orgańicas, Centro de Investigacioń Príncipe Felipe, C/ Eduardo Primo Yuf́era 3, 46012 Valencia, Spain Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel Lardizab́al 3, 20018 San Sebastian, Spain IKERBASQUE, Basque Foundation for Science, Alameda Urquijo, 36-5 Plaza Bizkaia, 48011 Bilbao, Spain Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Murmanska Street 1, 02660 Kyiv-94, Ukraine

Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).

2.4. Tandem sp-sp Coupling/Cyclization 3418 3. Cycloaddition Reactions 3418 3.1. [3+2] Cycloaddition 3418 3.1.1. Triazole/Isoxazole-Forming Reactions 3418 3.1.2. Reactions of Azomethine Ylides 3419 3.1.3. Cycloaddition of Nitrones 3422 3.1.4. Other [3+2] Reaction 3422 3.2. [4+2] Heterocycloaddition 3422 3.3. [2+2] Cycloaddition 3424 4. Cycloisomerization of Enynes/Diynes 3425 5. Intramolecular Friedel-Crafts-Type Reactions 3428 6. Reactions of R-Diazocarbonyl Compounds 3429 7. Aziridination of Olefins 3431 8. N/O-Vinylation/Arylation 3431 9. Radical Cyclization of Haloalkenes and Haloalkynes 3433

Coinage Metal-Assisted Synthesis of Heterocycles

II.2.1. Homogeneous Systems 2166 II.2.2. Heterogeneous Systems 2168 II.3. Hydride Transfer Reduction 2169 II.3.1. Homogeneous Systems 2169 II.3.2. Heterogeneous Systems 2171 II.4. Hydrosilylation 2172 III. C−O Bond Formation 2173 III.1. Epoxidation of Unfunctionalized Olefins 2173 III.1.1. Homogeneous Catalysis 2173 III.1.2. Heterogeneous System 2176 III.2. Dihydroxylation of Olefins 2178 III.2.1. Homogeneous Systems 2178 III.2.2. Heterogeneous System 2178 III.3. Ring Opening of Meso Epoxides 2180 III.4. Kinetic Resolution 2180 III.4.1. Terminal Epoxides 2180 III.4.2. Secondary Alcohols 2181 IV. C−H Bond Oxidation 2181 IV.1. Allylic and Benzylic Oxidation 2181 IV.2. Baeyer−Villiger-type Reaction 2181 IV.3. Wacker-type Cyclization 2182 V. S−O Bond Formation 2182 VI. C−N Bond Formation 2183 VI.1. Hydroboration/Amination 2183 VI.2. Enolate Amination 2183 VI.3. Aza-Claisen Rearrangement 2183 VI.4. Azide Synthesis 2184 VI.5. Aminohydroxylation 2184 VI.6. Aziridine Synthesis 2184 VI.7. C−N Bond Formation via S−N Bond Formation 2185

Nitrogen-containing ligands for asymmetric homogeneous and heterogeneous catalysis.

The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11 families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of cellular cN levels and, consequently, the actions of cN-signaling pathways. PDEs exhibit a range of catalytic efficiencies for breakdown of cAMP and/or cGMP and are regulated by myriad processes including phosphorylation, cN binding to allosteric GAF domains, changes in expression levels, interaction with regulatory or anchoring proteins, and reversible translocation among subcellular compartments. Selective PDE inhibitors are currently in clinical use for treatment of erectile dysfunction, pulmonary hypertension, intermittent claudication, and chronic pulmonary obstructive disease; many new inhibitors are being developed for treatment of these and other maladies. Recently reported x-ray crystallographic structures have defined features that provide for specificity for cAMP or cGMP in PDE catalytic sites or their GAF domains, as well as mechanisms involved in catalysis, oligomerization, autoinhibition, and interactions with inhibitors. In addition, major advances have been made in understanding the physiological impact and the biochemical basis for selective localization and/or recruitment of specific PDE isoenzymes to particular subcellular compartments. The many recent advances in understanding PDE structures, functions, and physiological actions are discussed in this review.

https://www.physiology.org/doi/pdf/10.1152/physrev.00030.2010

Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions

Purpose of reviewQuercetin is discussed since several decades as a multipotent bioflavonoid with great potential for the prevention and treatment of disease. In the current review, we present the most recent findings on quercetin with regard to the pharmacology, the in-vitro and in-vivo effects in d

Quercetin: potentials in the prevention and therapy of disease.

Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia

Asymmetric Synthesis of Cyclic Ethers by Rearrangement of Oxonium Ylides Generated from Chiral Copper Carbenoids

The clinical significance of phosphodiesterase 5 (PDE5) inhibition is increasingly understood following the pioneering work with sildenafil, and the continuing development programmes for both sildenafil and other marketed inhibitors. Since the initial launch of sildenafil for male erectile dysfunction (MED), approval has now been granted for treatment of pulmonary hypertension, whilst ongoing studies have indicated the potential of PDE5 inhibition for the treatment of a range of additional indications including cardioprotection, memory retention and diabetes. Many of these additional indications are best suited to chronic oral dosing and emphasise the need for highly selective inhibitors with extended duration of action. This article will focus on a research programme aimed at the discovery of improved second-generation PDE5 inhibitors. Essential features of these new PDE5 inhibitors would be enhanced selectivity across the whole PDE family and pharmacokinetics compatible with once daily dosing. Key elements used in this programme are high throughput screening (HTS), exploitation of co-crystal structural information for bound inhibitor in the PDE5 active site, and employment of parallel chemistry to speed progress. Under the guidance of co-crystal structural information, a non-selective HTS hit with poor physicochemistry was initially modified using parallel chemistry to give a lead compound (3) that established a new PDE5 inhibitor series. Notably, (3) displayed physicochemistry compatible with a long plasma half-life, and wide chemical scope. Subsequent optimisation of (3) using crystal structure information to guide design, led rapidly to highly potent and selective PDE5 inhibitors (47, 50). Continued focus on physical properties through ligand efficiency evaluation and lipophilicity (cLogP), maintained the inherently desirable physicochemistry of the initial lead.

Design of Second Generation Phosphodiesterase 5 Inhibitors

The invention provides compounds of formula (I), wherein R1 represents C?1-4? alkoxy optionally substituted by one or more fluorine atoms; R?2? represents H or C?1-6? alkoxy optionally substituted by one or more fluorine atoms; R?3? represents one or more groups independently selected from H, halogen, C?1-4? alkoxy and CF3; in addition, R?2? and one R3 group may together represent -OCH?2?-, the methylene group being attached to the ortho-position of the pendant phenyl ring; R?4? represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of inter alia benign prostatic hyperplasia.

Quinoline and quinazoline compounds useful in therapy

Compounds of formula (I) (the values of R1, R2, R3, R4, R5 and R6 are as defined in the description), pharmaceutical composition containing them and use thereof for manufacture of medicaments for treatment of hypertension.

Fox David Nathan Abraham

Papers

Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia

Asymmetric Synthesis of Cyclic Ethers by Rearrangement of Oxonium Ylides Generated from Chiral Copper Carbenoids

Design of Second Generation Phosphodiesterase 5 Inhibitors

Quinoline and quinazoline compounds useful in therapy

5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension